FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class Exposed, Relapsed or Refractory Multiple Myeloma.

Poornima Sharma, Xue Lin, Zhenzhen Xu,Bindu Kanapuru,Marc R Theoret, Robert Sokolic, Lola A Fashoyin-Aje

Clinical cancer research an official journal of the American Association for Cancer Research（2025）

引用 0|浏览0

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要